Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Equity (2021 - 2025)

ARS Pharmaceuticals' Return on Equity history spans 5 years, with the latest figure at 1.37% for Q4 2025.

  • For Q4 2025, Return on Equity fell 138.0% year-over-year to 1.37%; the TTM value through Dec 2025 reached 1.37%, down 138.0%, while the annual FY2025 figure was 0.92%, 96.0% down from the prior year.
  • Return on Equity for Q4 2025 was 1.37% at ARS Pharmaceuticals, down from 0.51% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.22% in Q1 2022 and bottomed at 1.37% in Q4 2025.
  • The 5-year median for Return on Equity is 0.18% (2023), against an average of 0.24%.
  • The largest annual shift saw Return on Equity increased 28bps in 2024 before it crashed -138bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.13% in 2021, then crashed by -147bps to 0.32% in 2022, then surged by 85bps to 0.05% in 2023, then skyrocketed by 116bps to 0.01% in 2024, then crashed by -18125bps to 1.37% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Return on Equity are 1.37% (Q4 2025), 0.51% (Q3 2025), and 0.26% (Q2 2025).